본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

The breast journal v.24 no.4, 2018년, pp.473 - 479   SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long‐term results from a single institution experience

Martin‐Romano, Patricia    (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spai  ); Baraibar, Iosune    (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spai  ); Espinós, Jaime    (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spai  ); Legaspi, Jairo    (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spai  ); López‐Picazo, Jose M.    (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spai  ); Aramendía, Jose Manuel    (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spai  ); Fernández, Oscar A.    (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spai  ); Santisteban, Marta    (Department of Medical Oncology. Clí  );
  • 초록  

    Abstract The combination of Pegylated Liposomal Doxorubicin (PLD) plus Gemcitabine (GEM) has been previously investigated in the treatment of metastatic breast cancer (MBC). PLD is a doxorubicin formulation with prolonged circulation time and better tissue distribution. GEM is a nucleoside analog with nonoverlapping toxicity compared to PLD. The aim of our study was to assess efficacy, toxicity, and long‐term outcome of this combination. Patients with heavily treated MBC were retrospectively analyzed. Chemotherapy consisted of PLD 25 mg/m 2 and GEM 800 mg/m 2 day 1, on a three‐week schedule. Cardiac function was evaluated baseline and during treatment. Radiological response was graded according to RECIST criteria v1.1. Toxicity was scored according to CTCAE v4.0. Progression‐free survival (PFS) and overall survival (OS) were evaluated. From 2001 to 2014, 122 pts were included. Median age was 55 (range: 28‐84). Median previous treatment schedules in the metastatic scenario were 3 (range: 1‐15). Most patients received prior anthracyclines (85%). Median number of metastatic sites was 2 (range: 1‐7). Median number of cycles delivered was 5 (range: 1‐36). Overall response rate was 31% (5% complete responses; 26% partial responses). Stable and progressive diseases were observed in 32% and 26% of patients. Grade ≥3 neutropenia was observed in 29 patients (24%). Grade ≥3 hand‐foot syndrome was detected in 17 patients (14%), mostly since cycle 3 (88%). Median cumulative PLD dose was 125 mg/m 2 . At a median follow‐up of 101 months, median PFS and OS were 7 and 22 months, respectively. PLD‐GEM combination achieves remarkable long‐term outcomes with an acceptable toxicity profile in patients with MBC.


  • 주제어

    chemotherapy combination .   gemcitabine .   metastatic breast cancer .   pegylated liposomal doxorubicin.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기